Literature DB >> 8733441

Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis.

M Gattorno1, P Picco, A Buoncompagni, F Stalla, P Facchetti, M P Sormani, V Pistoia.   

Abstract

OBJECTIVE: To determine the expression of tumour necrosis factor alpha (TNF alpha) and its soluble receptors (p55 and p75) in the sera and synovial fluid of patients with juvenile chronic arthritis (JCA), and their correlation with disease activity parameters.
METHODS: Ninety eight sera from 45 patients with JCA (14 systemic, 12 polyarticular, 19 pauciarticular), 20 sera from age matched healthy controls, and five synovial fluids from five antinuclear antibody (ANA) positive pauciarticular JCA patients were tested for the presence of TNF alpha, soluble TNF receptors p55 and p75 (sTNFRp55, sTNFRp75), and interleukin-6 (IL-6) by an enzyme amplified sensitivity immunoassay. Physician global estimate of disease activity, weekly fever score and joint score, C reactive protein (CRP), erythrocyte sedimentation rate (ESR), and haemoglobin concentration were evaluated as parameters of disease activity. The expression of p55 and p75 on peripheral mononuclear cells (MNCs) from five patients with systemic JCA and synovial MNCs from five ANA positive patients with pauciarticular JCA was evaluated by flow cytometry.
RESULTS: TNF alpha serum concentrations did not differ significantly between the patients with active JCA and the control group. No correlation was found between TNF alpha and parameters of disease activity, but both p55 and p75 showed a significant positive correlation with the physician global estimate of disease activity (p < 0.001), ESR (p < 0.001), CRP (p < 0.001), and serum concentrations of IL-6 (p < 0.001). Serum concentrations of haemoglobin correlated inversely with the concentrations of p55 and p75 (p < 0.001). Synovial lymphocytes selectively expressed the p75 surface receptor.
CONCLUSIONS: sTNFRp55 and sTNFRp75 each represent a sensitive marker of disease activity in JCA. Their increased expression in biological fluids may support the hypothesis that TNF alpha has a role in the pathogenesis of JCA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733441      PMCID: PMC1010145          DOI: 10.1136/ard.55.4.243

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

Review 1.  Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level.

Authors:  W Fiers
Journal:  FEBS Lett       Date:  1991-07-22       Impact factor: 4.124

Review 2.  TNF alpha--a pivotal role in rheumatoid arthritis?

Authors:  F M Brennan; R N Maini; M Feldmann
Journal:  Br J Rheumatol       Date:  1992-05

Review 3.  Soluble tumor necrosis factor receptors in arthritis.

Authors:  A P Cope; R N Maini
Journal:  J Rheumatol       Date:  1995-03       Impact factor: 4.666

4.  Cytokines in childhood rheumatic diseases.

Authors:  P Woo
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

5.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

6.  Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.

Authors:  A P Cope; D Aderka; M Doherty; H Engelmann; D Gibbons; A C Jones; F M Brennan; R N Maini; D Wallach; M Feldmann
Journal:  Arthritis Rheum       Date:  1992-10

7.  Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints.

Authors:  F M Brennan; D L Gibbons; T Mitchell; A P Cope; R N Maini; M Feldmann
Journal:  Eur J Immunol       Date:  1992-07       Impact factor: 5.532

8.  Soluble tumor necrosis factor receptors in human inflammatory synovial fluids.

Authors:  P Roux-Lombard; L Punzi; F Hasler; S Bas; S Todesco; H Gallati; P A Guerne; J M Dayer
Journal:  Arthritis Rheum       Date:  1993-04

9.  Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis.

Authors:  A M Prieur; M T Kaufmann; C Griscelli; J M Dayer
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

10.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  9 in total

1.  Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308GG genotype.

Authors:  Jelena Basic; Dusica Pavlovic; Tatjana Jevtovic-Stoimenov; Jelena Vojinovic; Gordana Susic; Ivana Stojanovic; Gordana Kocic; Vuk Milosevic; Tatjana Cvetkovic; Milena Marinkovic; Andrej Veljkovic
Journal:  J Physiol Biochem       Date:  2010-07-02       Impact factor: 4.158

2.  Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.

Authors:  M Shimizu; N Inoue; M Mizuta; Y Nakagishi; A Yachie
Journal:  Clin Exp Immunol       Date:  2017-09-15       Impact factor: 4.330

3.  Cytokines and juvenile idiopathic arthritis.

Authors:  Patricia Woo
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

4.  Serum interleukin 12 concentration in juvenile chronic arthritis.

Authors:  M Gattorno; P Picco; S Vignola; F Stalla; A Buoncompagni; V Pistoia
Journal:  Ann Rheum Dis       Date:  1998-07       Impact factor: 19.103

5.  Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models.

Authors:  Linda N Liu; Gang Wang; Kyle Hendricks; Keunmyoung Lee; Ernst Bohnlein; Uwe Junker; Joseph D Mosca
Journal:  Stem Cells Transl Med       Date:  2013-04-16       Impact factor: 6.940

Review 6.  Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.

Authors:  Susan Shenoi; Carol A Wallace
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

7.  Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis.

Authors:  K Shigehara; N Shijubo; M Ohmichi; K Kamiguchi; R Takahashi; S Morita-Ichimura; T Ohchi; T Tatsuno; Y Hiraga; S Abe; N Sato
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

8.  Soluble cytokine receptor levels in aqueous humour of patients with specific autoimmune uveitic entities: sCD30 is a biomarker of granulomatous uveitis.

Authors:  Ahmed M Abu El-Asrar; Nele Berghmans; Saleh A Al-Obeidan; Priscilla W Gikandi; Ghislain Opdenakker; Jo Van Damme; Sofie Struyf
Journal:  Eye (Lond)       Date:  2019-12-05       Impact factor: 3.775

9.  Modeling the impact of COPD on the brain.

Authors:  Soo Borson; James Scanlan; Seth Friedman; Elizabeth Zuhr; Julie Fields; Elizabeth Aylward; Rodney Mahurin; Todd Richards; Yoshimi Anzai; Michi Yukawa; Shingshing Yeh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.